Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?

Neurology

Volumn 46, Issue 5, 1996, Pages 1262-1269

  Damier, Philippe ^a   Kastner, Anne ^a   Agid, Yves ^a   Hirsch, Etienne C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

AGED; ARTICLE; BRAIN STEM; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; ENZYME LOCALIZATION; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NERVE CELL NECROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0029951445     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.46.5.1262     Document Type: Article

References (36)

1. Pearson J. Neurotransmitter immunohistochemistry in the study of human development, anatomy and pathology. Prog Neuropath 1983;5:41-97.
2. Hirsch EC, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
3. Hirsch EC. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann Neurol 1992;32:588-593.
4. Cohen G. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 1983;19:89-103.
5. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 1989;86:1398-1400.
6. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in human brain. Biochem Pharmacol 1968;17:1285-1297.
7. Glover V, Sandier M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B substrate in man. Nature 1977;265:80-81.
8. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-467.
9. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.
10. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225:1480-1482.
11. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long term study. J Neural Transm 1985;64:113-127.
12. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.
13. Konradi C, Svoma E, Jellinger K, Riederer P, Denney R, Thibault J. Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 1988;26:791-802.
14. Konradi C, Kornhuber J, Froelich L, et al. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neuroscience 1989;33:383-400.
15. Moll G, Moll R, Riederer P, Gsell W, Heinsen H, Denney RM. Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pilot study. J Neural Transm Suppl 1990;32:67-77.
16. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993;52:1-6.
17. Yong VW, Perry JL. Monoamine oxidase B, smoking and Parkinson's disease. J Neurol Sci 1986;72:265-272.
18. Graybiel AM, Hirsch EC, Agid YA. Differences in tyrosine hydroxylase-like immunoreactivity characterize the mesostriatal innervation of striosomes and extrastriosomal matrix at maturity. Proc Natl Acad Sci USA 1987;84:303-307.
19. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques - a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
20. Sternberger LA. Immunocytochemistry. New York: Wiley, 1979.
21. Hancock MB. Visualization of peptide-immunoreactive processes on serotonin-immunoreactive cells using two-color immunoperoxidase staining. J Histochem Cytochem 1984;32: 311-314.
22. Terry RD, De Teresa R, Hansen LA. Neocortical cell counts in normal adult aging. Ann Neurol 1987;21:530-539.
23. Olszewski J, Baxter D. Serial semischematic drawings and photomicrographs. In: Cytoarchitecture of the human brain stem. Basel: Karger, 1982:56-57.
24. Denney RM, Patel NT, Fritz RR, Abell CW. A monoclonal antibody elicited to human platelet monoamine oxidase. Mol Pharmacol 1982;22:500-508.
25. Westlund KN, Denney RM, Rose RM, Abell CW. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 1988;25: 439-456.
26. Steinbusch HWM. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 1981;6:557-618.
27. Felten DL, Sladek JR, Jr. Monoamine distribution in primate brain V. Monoamine nuclei: anatomy pathways and local organization. Brain Res Bull 1983;10:171-284.
28. Nobin A, Björklund A. Topography of the monoamine neuron systems in the human brain as revealed in fetuses. Acta Physiol Scand Suppl 1973;388:1-40.
29. Birkmayer W, Riederer P. Biochemistry: general principles of biochemical transmission. In: Parkinson's disease. New York: Springer-Verlag, 1983:16-17.
30. Javoy-Agid F, Ruberg M, Taquet H, et al. Biochemical neuropathology of Parkinson's disease. Adv Neurol 1984;40:189-197.
31. Jellinger K. The pathology of parkinsonism. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths, 1987:125-165.
32. Pavlin R. Monoamine oxidase activity in single nerve cell bodies from substantia nigra of rat and man. Experientia 1988; 44:710-712.
33. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
34. Kastner A, Anglade P, Bounaix C, et al. Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system. Neuroscience 1994;62:449-457.
35. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
36. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.